Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

A K Fielding; G A Zakout

doi:10.1007/s11899-013-0155-4

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

A K Fielding
, G A Zakout

The Hull York Medical School

Research output: Contribution to journal › Review article › peer-review

Abstract

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 % lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality--allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.

Original language	English
Pages (from-to)	98-108
Number of pages	11
Journal	Current hematologic malignancy reports
Volume	8
Issue number	2
DOIs	https://doi.org/10.1007/s11899-013-0155-4
Publication status	Published - Jun 2013

Keywords

Antineoplastic Agents/therapeutic use
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
Protein Kinase Inhibitors/therapeutic use
Remission Induction/methods

Access to Document

10.1007/s11899-013-0155-4

Cite this

@article{561f97dba3474c3cb26403eec0fa1f21,

title = "Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia",

abstract = "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 \% lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality--allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.",

keywords = "Antineoplastic Agents/therapeutic use, Combined Modality Therapy, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy, Protein Kinase Inhibitors/therapeutic use, Remission Induction/methods",

author = "Fielding, \{A K\} and Zakout, \{G A\}",

year = "2013",

month = jun,

doi = "10.1007/s11899-013-0155-4",

language = "English",

volume = "8",

pages = "98--108",

journal = "Current hematologic malignancy reports",

issn = "1558-8211",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Fielding, A K

AU - Zakout, G A

PY - 2013/6

Y1 - 2013/6

N2 - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 % lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality--allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.

AB - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)]. Previously perceived to confer poor outcome with at least 10 % lower chance of remission than standard-risk ALL. With the advent of targeted BCR-ABL specific tyrosine-kinase inhibitors (TKIs), higher remission rates were achieved, thus allowing more patients to proceed with the definitive treatment modality--allogeneic hematopoietic stem cell transplantation (alloHSCT). Prime challenges to treatment of Ph+ ALL include appropriate integration of TKIs into remission induction chemotherapeutic regimes, appropriate understanding and implementation of BCR-ABL monitoring for guiding therapeutic intervention(s), and minimizing transplant-related toxicities.

KW - Antineoplastic Agents/therapeutic use

KW - Combined Modality Therapy

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy

KW - Protein Kinase Inhibitors/therapeutic use

KW - Remission Induction/methods

U2 - 10.1007/s11899-013-0155-4

DO - 10.1007/s11899-013-0155-4

M3 - Review article

C2 - 23475624

SN - 1558-8211

VL - 8

SP - 98

EP - 108

JO - Current hematologic malignancy reports

JF - Current hematologic malignancy reports

IS - 2

ER -